Clinical commissioning policy: human normal immunoglobulin for treatment of scleromyxedema (adults)

Document first published:
Page updated:
Topic:
Publication type:

Human normal immunoglobulin is recommended to be available as a routine commissioning treatment option for scleromyxedema within the criteria set out in this document.

Document

Clinical commissioning policy: human normal immunoglobulin for treatment of scleromyxedema (adults)

Clinical commissioning policy: human normal immunoglobulin for treatment of scleromyxedema (adults)

  • PDF
  • 322 KB
  • 10 pages

Document

Equality and health inequalities impact assessment: human normal immunoglobulin for treatment of scleromyxedema (adults)

Equality and health inequalities impact assessment: human normal immunoglobulin for treatment of scleromyxedema (adults)

  • PDF
  • 135 KB
  • 10 pages

Document

Evidence review: human normal immunoglobulin for treatment of scleromyxedema (adults)

Evidence review: human normal immunoglobulin for treatment of scleromyxedema (adults)

  • PDF
  • 483 KB
  • 41 pages

Document

Engagement report: human normal immunoglobulin for treatment of scleromyxedema (adults)

Engagement report: human normal immunoglobulin for treatment of scleromyxedema (adults)

  • PDF
  • 145 KB
  • 3 pages

Document

Clinical panel report: human normal immunoglobulin for treatment of scleromyxedema (adults)

Clinical panel report: human normal immunoglobulin for treatment of scleromyxedema (adults)

  • PDF
  • 122 KB
  • 4 pages

Document

Clinical priorities assurance group report: human normal immunoglobulin for treatment of scleromyxedema (adults)

Clinical priorities assurance group report: human normal immunoglobulin for treatment of scleromyxedema (adults)

  • PDF
  • 172 KB
  • 9 pages